IMTXImmatics N.V.vs its industry peers
A metric-by-metric comparison of Immatics N.V. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMTXEsta | $924M#4 | — | — | — | — | — | — | — | — | — | -25.5%#5 | — |
| EVAX | $1.2B#3 | — | — | 165.1x#3 | 125.1%#3 | 27.1%#3 | -122.7%#3 | — | — | — | -47.1%#8 | — |
| FENC | $362M#5 | — | 8.5x#2 | 8.1x#2 | -6.1%#5 | -2134.2%#7 | -14.1%#2 | -22951.3%#2 | -23.1%#2 | — | 28.1%#1 | — |
| GNTA | $22M#9 | — | — | — | — | — | — | — | — | — | -62.9%#9 | — |
| GPLB | — | — | — | — | — | -0.8%#4 | — | — | — | — | — | — |
| IMCR | $1.5B#2 | — | 3.6x#1 | 3.8x#1 | 29.0%#4 | 30.5%#2 | -11.3%#1 | -8.5%#1 | -12.1%#1 | — | -8.3%#3 | — |
| IPHA | $127M#7 | — | — | — | — | — | — | — | — | — | -27.0%#6 | — |
| MEOBF | — | — | — | — | 191.4%#1 | -16.1%#5 | — | — | — | — | — | — |
| MESO | $18.5B#1 | — | — | 1076.4x#4 | 191.4%#1 | -16.1%#5 | — | — | — | — | -8.4%#4 | — |
| MOLN | $155M#6 | — | — | — | — | — | — | — | — | — | 0.8%#2 | — |
| OKYO | $73M#8 | — | — | — | — | 72.0%#1 | — | — | — | — | -46.4%#7 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-05.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice